Year: 2022

BRENTWOOD, Tenn., Dec. 06, 2022 (GLOBE NEWSWIRE) — CoreCivic, Inc. (NYSE: CXW) (CoreCivic or the Company) announced today it received notice from the California Department of Corrections and Rehabilitation (CDCR) of its intent to terminate the lease agreement for the company-owned, 2,560-bed California City Correctional Center (CCCC) by March 31, 2024, due to the state’s declining inmate population. The lease agreement is fully funded through the current fiscal year ending June 30, 2023. Funding for the lease of the CCCC for the 2024 fiscal year, beginning July 1, 2023, will be determined in the California legislature in the first half of 2023 as part of the annual budget process. As part of this process the Company plans to engage with the state of California regarding the continued utilization of the CCCC by the CDCR due...

Industry leaders join forces to support the marine shipping industry’s path to decarbonization VANCOUVER, British Columbia, Dec. 06, 2022 (GLOBE NEWSWIRE) — Waterfront Shipping, a subsidiary of Methanex, the world’s largest producer and supplier of methanol, announced today it has entered into a time-charter agreement with Trafigura, one of the world’s largest physical commodity trading groups. Under the agreement, Trafigura will operate the co-owned Waterfront Shipping and Clean Sea medium-range product tanker, Mari Innovator, as part of its global network of vessels used in clean products trading routes. This agreement supports the parties’ efforts to help transition the marine shipping industry toward decarbonization and is another example of Waterfront Shipping’s leadership in supporting the growing demand for methanol...

Company engages Axiom Exploration Group & Mira Geoscience VANCOUVER, British Columbia, Dec. 06, 2022 (GLOBE NEWSWIRE) — Clear Sky Lithium Corp. (CSE: POWR) (FRA: K4A / WKN: A3DM2W) (OTCQB: CSKYF) (“Clear Sky” or the “Company”), a mineral exploration and development company focused on American lithium deposits to support domestic demand, is pleased to announce that it has engaged Axiom Exploration Group and Mira Geoscience to complete a geophysics program at the Halo Project in Big Smoky Valley, Nevada. Company CEO, Patrick Morris, said, “Clear Sky continues to execute on our exploration and development plan, with our two-pronged approach to unlocking the claystone value. While our metallurgical team is hard at work with the processing and extraction technology, our exploration team continues to build out our geological understanding...

WINNIPEG, Manitoba, Dec. 06, 2022 (GLOBE NEWSWIRE) — DELTA 9 CANNABIS INC. (TSX: DN) (OTCQX: DLTNF) (“Delta 9” or the “Company”) is pleased to announce that it has established an at-the-market equity program (the “ATM Program”) that allows the Company to issue up to $5,000,000 of common shares in the capital of the Company (the “Common Shares”) from treasury to the public from time to time, at the Company’s discretion. Distributions of the Common Shares through the ATM Program will be made pursuant to the terms of an equity distribution agreement (the “Equity Distribution Agreement”) dated December 6, 2022 between the Company and Haywood Securities Inc. (the “Agent”). Pursuant to the Equity Distribution Agreement, the Common Shares may be offered and sold by the Agent: (a) in privately negotiated transactions with the consent of...

PHILADELPHIA, Dec. 06, 2022 (GLOBE NEWSWIRE) — Brandywine Realty Trust (the “Company”) (NYSE:BDN) announced today that its operating partnership, Brandywine Operating Partnership, L.P. (the “Operating Partnership”), has priced an underwritten public offering of $350 million of its 7.550% guaranteed notes due 2028 (the “Notes”). Interest on the Notes will be payable semi-annually on March 15 and September 15 of each year, commencing March 15, 2023. The Notes are being offered to investors at a price of 99.058% of their principal amount, plus accrued interest, if any, from December 13, 2022, with a re-offer yield of 7.776%. The sale of the Notes is expected to close on December 13, 2022, subject to customary closing conditions. The net proceeds of the offering, after deducting underwriting discounts and estimated transaction expenses...

BOSTON, Dec. 06, 2022 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, announced today that it has commenced an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof) and accompanying warrants to purchase shares of its common stock (or pre-funded warrants). In addition, X4 expects to grant the underwriters a 30-day option to purchase additional shares of its common stock and/or warrants to purchase shares of its common stock at the public offering price, less the underwriting discounts and commissions. All of the securities in the offering will be sold by X4. The offering is subject to market and other conditions,...

BROOKINGS, S.D., Dec. 06, 2022 (GLOBE NEWSWIRE) — Daktronics Inc (Nasdaq – DAKT) announced today that in light of the Company’s announcement in its Current Report on Form 8-K filed today with the Securities and Exchange Commission, it has changed the date and time of its previously announced earnings release and conference call and webcast for its second quarter fiscal 2023 financial results. The Company will now release the second quarter fiscal 2023 financial results on Monday, December 12, 2022, before the market opens. The Company will host a conference call and webcast for all interested parties at 10:00 AM CT that day. Reece A. Kurtenbach, Chief Executive Officer, and Sheila M. Anderson, Chief Financial Officer, will host the conference call, which will contain forward-looking statements and other material information. To...

LA JOLLA, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s Chief Medical Officer, Kazuko Matsuda, MD PhD MPH, presented positive results from a subgroup analysis of the completed Phase 2 clinical trial which evaluated MN-001 (tipelukast) for the treatment of hypertriglyceridemia at the International Diabetes Federation (IDF) World Diabetes Congress 2022 held online December 5 – 8, 2022. In the completed Phase 2 study, MN-001 (tipelukast) significantly reduced serum triglycerides in participants with non-alcoholic fatty liver disease (NAFLD) and hypertriglyceridemia (HTG). Subsequent in vitro results revealed that MN-001 (tipelukast)...

Completes business combination with Lakeshore Acquisition I Corp. ProSomnus common stock will trade on Nasdaq Capital Market under ticker symbol “OSA” SAN FRANCISCO, Dec. 06, 2022 (GLOBE NEWSWIRE) —  ProSomnus, Inc. (“the Company”), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced the completion of its previously announced business combination with Lakeshore Acquisition I Corp. (“Lakeshore”) (Nasdaq: LAAA), a publicly traded special purpose acquisition company. ProSomnus will commence trading on the Nasdaq Global Market under the symbol “OSA” on Dec. 7, 2022. The business combination, which was approved by Lakeshore’s shareholders on Dec. 2, 2022, along with the convertible debt issued in connection with the transaction, provides access to capital that will be used to drive...